Ligand buys Santen's Ryjunea royalty rights for $23M upfront

LIGAND PHARMACEUTICALS INC

$23M upfront acquires 100% interest in tiered low-double-digit-to-high-teens royalty on Ryjunea EMEA net sales.
Ryjunea is EU/UK's first approved pharmacologic treatment to slow pediatric myopia; EC approved June 2025, UK MHRA Oct 2025.
Santen licensed EMEA rights from Sydnexis in 2021; Ligand steps into those payment rights; Sydnexis keeps US and other territories.
Market: ~14M myopia patients in Europe 2025; 1 in 3 children projected affected by 2050.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.